If FCR would be the cure of decision, caution need to be taken in individuals with NOTCH1 mutations, in whom rituximab appears to acquire small extra benefit.59 Other genomic subgroups, including individuals with BIRC3 mutations look to derive very little gain from CIT,111,112 but these benefits really should be more https://oviniv753owe9.wikifordummies.com/user